ArticleCureus2025
Silent Threats to the Liver: Acute Hepatotoxicity Attributed to Selective Androgen Receptor Modulators (SARMs).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective androgen receptor modulators (SARMs) have garnered significant attention in recent years due to their potential to improve muscle mass and athletic performance with reduced androgenic side effects compared to traditional anabolic steroids. However, despite their growing popularity, there is increasing evidence linking SARMs to acute liver injury, raising concerns regarding their safety profile. SARMs can disrupt normal liver function through various pathways, including oxidative stress, alterations in lipid metabolism, and direct hepatocellular toxicity. This article explores the association between SARMs and acute liver injury, examining the mechanisms of hepatotoxicity, clinical manifestations, and potential therapeutic approaches. The findings underscore the need for further research and regulatory oversight in using SARMs, particularly in non-medical and performance-enhancing contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.